WO2012150839A2 - 포스파티딜세린의 마이크로캡슐화 방법 - Google Patents
포스파티딜세린의 마이크로캡슐화 방법 Download PDFInfo
- Publication number
- WO2012150839A2 WO2012150839A2 PCT/KR2012/003504 KR2012003504W WO2012150839A2 WO 2012150839 A2 WO2012150839 A2 WO 2012150839A2 KR 2012003504 W KR2012003504 W KR 2012003504W WO 2012150839 A2 WO2012150839 A2 WO 2012150839A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphatidylserine
- oil
- starch
- lecithin
- emulsion
- Prior art date
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 110
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 229920002472 Starch Polymers 0.000 claims abstract description 46
- 235000019698 starch Nutrition 0.000 claims abstract description 46
- 239000008107 starch Substances 0.000 claims abstract description 46
- 239000007788 liquid Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims description 28
- 239000003925 fat Substances 0.000 claims description 18
- 239000003094 microcapsule Substances 0.000 claims description 18
- 235000019197 fats Nutrition 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 14
- 239000000787 lecithin Substances 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 229940067606 lecithin Drugs 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 241000237852 Mollusca Species 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 102000011420 Phospholipase D Human genes 0.000 claims description 2
- 108090000553 Phospholipase D Proteins 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 239000008171 pumpkin seed oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 229940018044 saw palmetto fruit extract Drugs 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 abstract description 4
- 239000004368 Modified starch Substances 0.000 abstract description 3
- 235000019426 modified starch Nutrition 0.000 abstract description 3
- 230000001804 emulsifying effect Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 239000011162 core material Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- PS phosphatidlyserine
- Microencapsulation technology is a method to protect the core material from the external environment or to release it at a desired rate under certain conditions by forming a film using a coating material on the core material in a solid, liquid, or gas phase. It can be applied to a wide range of fields such as medicine, food, and cosmetics.It can protect unstable cores from external factors, reduce losses, isolate highly reactive cores, and conceal or solidify toxic, odor and taste. It is used for the purpose of simplifying, controlling the elution rate of the contents, and the like.
- microencapsulation of highly reactive bioactive ingredients and food materials has the advantages of preventing oxidation and preservation, blocking unwanted flavors, controlling release, enhancing bioavailability, and improving handling and processability by changing physical properties.
- the coating material of the capsule used in food must be edible, excellent in dissolution, high in emulsification, and easy to operate during microencapsulation. It should also be less reactive with the core material during processing and storage, protect the core material from the external environment, and be economical due to its low price.
- Carbohydrates, gelatin, cellulose, fats, proteins, gums and the like are used as coating materials, and microencapsulation methods for coating with various coating materials have been studied to overcome disadvantages of highly reactive materials.
- Phosphatidylserine is a kind of phospholipid (Phospholipid) existing in nature, and is composed of a serine group (hydrophilic moiety), a phosphate group, glycerol and two fatty acid groups (hydrophobic moiety).
- lecithin In the human brain, lecithin accounts for almost half of the dry weight, and most of the lecithin is contained in the membranes of nerve cells. Lecithin, an important component of the cell membrane, contains phosphatidylserine, which is particularly present in the brain, and constitutes a neural cell membrane, releasing energy for life-sustaining activity, releasing neurotransmitters or synapses. It is known that he is deeply involved in the expression of neurons' function, such as information transmission. For this reason, phosphatidylserine is sometimes called the "nutrient of the brain.”
- Phosphatidylserine has been subject to dozens of clinical trials since it was first isolated by Jordi Folch in 1942. As a result, phosphatidylserine has been shown to be effective in improving Alzheimer's dementia and in reducing brain function due to aging. have. In addition to the effects of improving brain function, it has been reported to show effects such as improvement in epilepsy, stress tolerance, and recovery of hormone secretion rhythm.
- Phosphatidylserine has been reported to be effective only when ingested from 100 to 300 mg / day (day), but the supply through food is limited, and the supply through a variety of manufacturing is actively considered (Korea Patent Publication No. 2002-0085756 Reference).
- Korean Patent Laid-Open Publication No. 2003-0058839 discloses a liquid composition in which medium chain fat is further added to a composition including phosphatidylserine and fats and oils. Such liquid compositions are described as being able to prevent phenomena of increasing viscosity or curing when phosphatidylserine is dissolved in an oil containing unsaturated fatty acids, and furthermore, it can be used in health foods and medicines in the form of soft capsules and the like.
- the water dispersibility of phosphatidylserine is not good, and even when dispersed in an aqueous solution, the ester bond of phosphatidylserine is gradually hydrolyzed naturally in the aqueous phase, and also has a relatively low oxidation stability.
- An object of the present invention is to provide a method for microencapsulating phosphatidylserine using starch as a coating material, to improve dispersibility, solubility, and stability in an aqueous solution of phosphatidylserine, and to prevent oxidation by oxygen in light or air. Can improve the long-term preservation and transport properties while maintaining the intrinsic function of phosphatidylserine.
- Another object of the present invention is to provide a microcapsule preparation preparable by the above method.
- the present invention comprises the steps of (a) dissolving phosphatidylserine in edible oil to prepare a phosphatidylserine liquid composition; (b) preparing a starch aqueous solution by mixing the processed starch modified with lipophilic and hydrophilicity with water before, after or simultaneously with step (a); (c) mixing and homogenizing the aqueous starch solution and the phosphatidylserine liquid composition to emulsify; And (d) provides a method for microencapsulation of phosphatidylserine, comprising the step of drying the obtained emulsion.
- the present invention provides a microcapsule formulation comprising phosphatidylserine suitable for food or pharmaceutical use, which can be prepared by the above-described method.
- the microencapsulation method of phosphatidylserine according to the present invention can prevent phosphatidylserine from being oxidized by oxygen in light or air, improve dispersibility, solubility, stability in water, and improve storage and transport characteristics.
- phosphatidylserine can be effectively formulated into capsule formulations such as health functional foods (particularly beverages) and medicines while maintaining phosphatidylserine-specific functions such as preventing cognitive decline and reducing stress.
- the present invention is a method for microencapsulating phosphatidylserine having a function such as improvement of memory, dementia improvement, improvement of epilepsy, stress resistance, recovery of hormonal secretion rhythm using starch which is a biodegradable polymer material.
- phosphatidylserine having a function such as improvement of memory, dementia improvement, improvement of epilepsy, stress resistance, recovery of hormonal secretion rhythm using starch which is a biodegradable polymer material.
- starch which is a biodegradable polymer material.
- it provides a method of microencapsulating in powder form.
- the phosphatidylserine liquid composition according to the present invention is prepared by dissolving phosphatidylserine in powder or granule form in an edible oil and fat.
- Phosphatidylserine in the form of a powder is difficult to be incorporated into lipophilic modified starch because the powder particles do not dissolve well in water and have a hydrophilic part and a hydrophobic part together due to the nature of phospholipids. Therefore, it is important to dissolve phosphatidylserine using edible oils and oils to make the oil type closer to lipophilic.
- the phosphatidylserine is a natural phosphatidylserine derived from animal tissues; Natural phosphatidylserine derived from plant tissues; A phosphatidylserine obtained by reacting lecithin selected from the group consisting of soybean lecithin, rapeseed lecithin, fish-derived lecithin, mollusk-derived lecithin and egg yolk lecithin with serine in the presence of phospholipase D, a saturated fatty acid having 6 to 30 carbon atoms, mono- Unsaturated fatty acids or polyunsaturated fatty acids, or phosphatidylserine, including sodium salts, potassium salts, magnesium salts, ammonium salts, phosphate salts, hydrochloride salts or sulfate salts thereof.
- Edible oil and fat may be at least one selected from medium chain fat, soybean oil, sunflower oil, grape seed oil, rapeseed oil, olive oil, corn oil, pumpkin seed oil, safflower seed oil, palm oil and the like.
- medium chain fat refers to an oil or fat consisting of fatty acids having 6 to 10 carbon atoms.
- Medium chain fat can be absorbed without pancreatic lipase and bile, and has an advantage that the absorption rate is four times faster than long chain fat and does not become accumulated fat. It is also more polar than long chain fats and is well suited for solubilizing phosphatidylserine.
- the phosphatidylserine liquid composition may further include one or more functional ingredients such as fish oil, saw palmetto fruit extract, vitamins, fragrances including DHA or EPA.
- Powdered or granular phosphatidylserine and edible oils used in the present invention may be used by removing all organic solvents by concentration under reduced pressure after dissolving in an organic solvent.
- the organic solvent may be used alone or in combination of two or more common organic solvents, such as ethanol, propanol, hexane, cyclohexane.
- Phosphatidylserine may be included in 10 to 50% by weight based on the total weight of the composition, but is not limited thereto.
- Starch is used as the outer wall material of the phosphatidylserine powder capsule of the present invention.
- the use of starch makes the film constituting the surface rough, but has a firm and flexible elasticity and impact resistance, and a formulation having excellent properties of protecting internal materials from oxidation is obtained.
- Processed starch used as coating material can be used to heat unmodified starch, enzymes (e.g. hydrolases, isomerases, oxidases, branching enzymes, etc.), acids (e.g. succinic acid, succinic acid, acetic acid).
- (Modified) starch obtained by treatment with hydrochloric acid, etc.) unlike ordinary starch, it has both hydrophilic and lipophilic properties, and has stable emulsion formation and excellent film forming ability.
- the starch may be used at about 5 to 30 times (w / w), preferably 5 to 15 times (w / w) of water at 50 to 90 ° C, preferably at 80 ° C.
- Preparation of the starch aqueous solution may be carried out before, after or simultaneously with the step of preparing the phosphatidylserine liquid composition described above.
- the starch aqueous solution may contain maltodextrin, arabic gum, guar gum, xanthan gum, sodium casein, gelatin, lecithin, sodium alginate, etc. to suppress elution of phosphatidylserine incorporated into starch and at the same time improve dispersibility in aqueous solution. It may further comprise one or more excipients.
- the first starch aqueous solution and the phosphatidylserine liquid composition prepared above are mixed and homogenized at 1,000 to 10,000 rpm for 5 to 10 minutes to obtain a first emulsion, and then a high pressure homogenizer, an ultrasonic emulsifier, etc. is used to increase the composition stability.
- the first emulsion may be further homogenized for 10 to 30 minutes at a pressure condition of 200 to 300 bar to obtain a secondary emulsion.
- phosphatidylserine may be mixed in an amount of 20 to 50 parts by weight based on 100 parts by weight of starch.
- Phosphatidylserine may be 1 to 30% by weight, preferably 3 to 20% by weight, based on the total weight of the mixture. If the phosphatidylserine content is less than 1% by weight, it is difficult to maintain the concentration that exerts the bioactive function in the final product, and if it exceeds 30% by weight, the emulsion stability may be deteriorated.
- Secondary emulsification may be carried out one or more times to stabilize the composition.
- Heat may be generated during the first and second emulsification, but the homogenization temperature may be generally 30 to 60 ° C, preferably 50 ° C. If the homogenization temperature exceeds 60 °C, the rancidity of phosphatidylserine can be promoted, if less than 30 °C the coating material can be hardened to reduce the stability of the capsule. At about 50 ° C., the degree of gelatinization of the internal and coating materials can be kept uniform, and is particularly effective in suppressing the rancidity of phosphatidylserine.
- At least one of the primary emulsion and the secondary emulsion is maltodextrin, arabic gum, guar gum, xanthan gum, casein sodium, gelatin, lecithin to inhibit elution of phosphatidylserine incorporated into starch and at the same time improve dispersibility in aqueous solution.
- excipients such as sodium alginate.
- secondary encapsulation may be performed with another coating to improve acid resistance, shelf life, transportability, and the ability to protect the internals from oxidation.
- Coating materials used for secondary encapsulation include, but are not limited to, whey protein, cyclodextrin, maltodextrin, sodium casein, gelatin, starch, and the like.
- phosphatidylserine may be microencapsulated and powdered at the same time as it is dried.
- Continuous powder drying or fluidized bed drying may be used to powder the final product.
- spray drying is performed by using a nozzle having a size of 1 to 5 mm at a temperature of 150 to 200 ° C. of a hot air blower, a temperature of 100 to 150 ° C. of a nozzle part, and a temperature of 40 to 100 ° C. of a cyclone part. It can be carried out by spraying.
- the average particle diameter of the microcapsules obtained after drying may range from approximately 400 to 700 nm.
- the microcapsules prepared by the above method can improve dispersibility, solubility and stability in aqueous solution of phosphatidylserine, prevent oxidation by oxygen in light or air, and maintain the intrinsic function of phosphatidylserine for a long time. It is possible to improve the preservation and transport properties, and furthermore, to contain phosphatidylserine at high concentrations, thereby increasing the ability to be used as medicines, foods (health functional foods), etc., which are mainly composed of phosphatidylserine.
- the present invention therefore also provides a microcapsule formulation comprising phosphatidylserine suitable for food or pharmaceutical use, which may be prepared by the methods described above.
- phosphatidylserine suitable for food or pharmaceutical use, which may be prepared by the methods described above.
- the content of phosphatidylserine may vary depending on the effective amount in the end use, but may be 1 to 25% by weight based on the total weight of the microcapsules.
- phosphatidylserine powder PS40SW of Doosan Co., Ltd.
- 60 g of soybean oil Welga Co., Ltd.
- the mixture was stirred until completely clear and dried under reduced pressure to prepare a liquid composition containing 25% by weight of phosphatidylserine.
- the processed starch substituted with 40 g of succinic acid was mixed with 540 g of sterile water, gelatinized at 80 ° C, and then cooled to 50 ° C.
- An emulsion was prepared.
- the primary emulsion was further homogenized by two passes of a 250 bar high pressure homogenizer to increase the stability of the composition. Then at 180 ° C Spray drying for 2 hours and powdered to prepare microcapsules (containing 10% by weight of phosphatidylserine) having an average particle diameter of 527 nm.
- the average particle diameter of the microcapsules is a value measured after diluting the aqueous capsule solution with sterile tertiary distilled water using Zeta PALS.
- the processed starch substituted with 60 g of succinic acid was mixed with 520 g of sterile water, gelatinized at 80 ° C, and then cooled to 50 ° C.
- the primary emulsion was further homogenized by two passes of a 250 bar high pressure homogenizer to increase the stability of the composition. After spray drying for 2 hours at 180 °C to powder to prepare a microcapsules (containing 6% by weight of phosphatidylserine) with an average particle diameter of 542 nm.
- the processed starch substituted with 60 g of succinic acid was mixed with 520 g of an aqueous solution added with 3% by weight of arabic gum, gelatinized at 80 ° C, and then cooled to 50 ° C.
- the primary emulsion was further homogenized by two passes of a 250 bar high pressure homogenizer to increase the stability of the composition. After spray drying at 180 ° C for 2 hours to form a microcapsules (containing 6% by weight of phosphatidylserine) with an average particle diameter of 487 nm.
- the processed starch substituted with 60 g of succinic acid was mixed with 520 g of an aqueous solution to which 1 wt% xanthan gum was added, gelatinized at 80 ° C, and then cooled to 50 ° C.
- the primary emulsion was further homogenized by two passes of a 250 bar high pressure homogenizer to increase the stability of the composition. After spray drying for 2 hours at 180 °C to powder to prepare a microcapsules (containing 6% by weight of phosphatidylserine) of an average particle diameter of 475 nm.
- the processed starch substituted with 40 g of succinic acid was mixed with 520 g of sterile water, gelatinized at 80 ° C, and then cooled to 50 ° C.
- Example 1 Example 2
- Example 3 Example 4
- Comparative Example 1 Comparative Example 2 0 days ⁇ ⁇ ⁇ ⁇ ⁇ X 30 days ⁇ ⁇ ⁇ ⁇ ⁇ X X 60 days ⁇ ⁇ ⁇ ⁇ ⁇ X X 90 days ⁇ ⁇ ⁇ ⁇ ⁇ X X
- the phosphatidylserine-containing microcapsules prepared according to the method of the present invention can be seen that the water dispersibility and stability is very good because it is maintained at 4 °C for more than 3 months without precipitation and layer separation. . It can also be seen that microcapsule formulations in a very stable form are obtained for formulations which have been added with excipients or using additional coating materials other than starch.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280033216.7A CN103635181A (zh) | 2011-05-04 | 2012-05-04 | 磷脂酰丝氨酸的微胶囊化方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110042580A KR101763947B1 (ko) | 2011-05-04 | 2011-05-04 | 포스파티딜세린의 마이크로캡슐화 방법 |
KR10-2011-0042580 | 2011-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012150839A2 true WO2012150839A2 (ko) | 2012-11-08 |
WO2012150839A3 WO2012150839A3 (ko) | 2013-01-03 |
Family
ID=47108156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/003504 WO2012150839A2 (ko) | 2011-05-04 | 2012-05-04 | 포스파티딜세린의 마이크로캡슐화 방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101763947B1 (zh) |
CN (1) | CN103635181A (zh) |
WO (1) | WO2012150839A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110583801A (zh) * | 2019-10-17 | 2019-12-20 | 东北农业大学 | 一种辛烯基琥珀酸酐改性淀粉与黄原胶复合制备粉末油脂的方法 |
CN111363767A (zh) * | 2020-04-22 | 2020-07-03 | 山东惠仕莱生物科技有限公司 | 一种食品用磷脂酰丝氨酸的制备方法 |
CN116570018A (zh) * | 2023-04-19 | 2023-08-11 | 广东萃怪香料有限公司 | 一种香料缓释纳米粒子及其制备方法和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103892281B (zh) * | 2014-04-11 | 2016-04-06 | 内蒙古伊利实业集团股份有限公司 | 含磷脂酰丝氨酸的营养组合物及其制备方法与应用 |
CN109222109A (zh) * | 2017-12-15 | 2019-01-18 | 理星(天津)生物科技有限公司 | 一种磷脂酰丝氨酸微丸及其制备方法和应用 |
CN108142950A (zh) * | 2017-12-27 | 2018-06-12 | 浙江健智元生物科技有限公司 | 一种改善脑部神经的元宝枫籽油复合纳米微囊粉及其制备方法 |
CN109568292A (zh) * | 2018-12-29 | 2019-04-05 | 中山百灵生物技术有限公司 | 一种含gpc的微凝胶及其制备方法 |
CN110368362B (zh) * | 2019-08-01 | 2022-10-04 | 聊城大学 | 一种磷脂酰丝氨酸乳剂的制备方法 |
CN110692893A (zh) * | 2019-11-12 | 2020-01-17 | 南通厚元生物科技有限公司 | 一种含有磷脂酰丝氨酸和ω-3脂肪酸的固体饮料制备方法 |
CN111418846A (zh) * | 2020-04-27 | 2020-07-17 | 南通厚元生物科技有限公司 | 含工业大麻蛋白和磷脂酰丝氨酸的微胶囊粉末及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011178A1 (de) * | 1990-01-26 | 1991-08-08 | Fluntera Ag | Einkapselung von wirkstoffen mittels stärke |
KR20020091492A (ko) * | 2001-05-30 | 2002-12-06 | 문장조 | 다공성 전분을 내부 매트릭스로한 마이크로캡슐 및 그의제조방법 |
KR20030058839A (ko) * | 2002-01-02 | 2003-07-07 | 주식회사 두산 | 포스파티딜세린 함유 액상 조성물 및 그 제조방법 |
KR20030070798A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 다당류 및 단백질 물질로 미세캡슐화된 지용성 항산화제및 그의 제조 방법 |
KR20080014379A (ko) * | 2006-08-11 | 2008-02-14 | 주식회사 두산 | 포스파티딜세린 함유 고체 지질 나노입자 조성물 및 그의제조방법 |
-
2011
- 2011-05-04 KR KR1020110042580A patent/KR101763947B1/ko active IP Right Grant
-
2012
- 2012-05-04 CN CN201280033216.7A patent/CN103635181A/zh active Pending
- 2012-05-04 WO PCT/KR2012/003504 patent/WO2012150839A2/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011178A1 (de) * | 1990-01-26 | 1991-08-08 | Fluntera Ag | Einkapselung von wirkstoffen mittels stärke |
KR20020091492A (ko) * | 2001-05-30 | 2002-12-06 | 문장조 | 다공성 전분을 내부 매트릭스로한 마이크로캡슐 및 그의제조방법 |
KR20030058839A (ko) * | 2002-01-02 | 2003-07-07 | 주식회사 두산 | 포스파티딜세린 함유 액상 조성물 및 그 제조방법 |
KR20030070798A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 다당류 및 단백질 물질로 미세캡슐화된 지용성 항산화제및 그의 제조 방법 |
KR20080014379A (ko) * | 2006-08-11 | 2008-02-14 | 주식회사 두산 | 포스파티딜세린 함유 고체 지질 나노입자 조성물 및 그의제조방법 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110583801A (zh) * | 2019-10-17 | 2019-12-20 | 东北农业大学 | 一种辛烯基琥珀酸酐改性淀粉与黄原胶复合制备粉末油脂的方法 |
CN111363767A (zh) * | 2020-04-22 | 2020-07-03 | 山东惠仕莱生物科技有限公司 | 一种食品用磷脂酰丝氨酸的制备方法 |
CN116570018A (zh) * | 2023-04-19 | 2023-08-11 | 广东萃怪香料有限公司 | 一种香料缓释纳米粒子及其制备方法和应用 |
CN116570018B (zh) * | 2023-04-19 | 2024-01-02 | 广东萃怪香料有限公司 | 一种香料缓释纳米粒子及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103635181A (zh) | 2014-03-12 |
KR101763947B1 (ko) | 2017-08-01 |
KR20120124745A (ko) | 2012-11-14 |
WO2012150839A3 (ko) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012150839A2 (ko) | 포스파티딜세린의 마이크로캡슐화 방법 | |
US6444242B1 (en) | Microencapsulated oil or fat product | |
KR101156789B1 (ko) | 젤라틴 피막용 조성물, 젤라틴 피막, 및 이를 이용한 캡슐제 | |
WO2016117621A1 (ja) | ω3脂肪酸の自己乳化組成物 | |
CN107362154A (zh) | 具有改进壳层的微胶囊 | |
JPH02103289A (ja) | 魚油のマイクロカプセル化 | |
US10898442B2 (en) | Microencapsulates containing stabilised lipid, and methods for the production thereof | |
US20060128665A1 (en) | Marine lipid compositions | |
CN102724972A (zh) | 脂肪酸油混合物的包衣胶囊和包衣片剂 | |
TW200534864A (en) | S/O type pharmaceutical preparation and process for producing the same | |
US20230248808A1 (en) | Joint Health Composition and Use Thereof in Healthy Mammals | |
Zeng et al. | A nanoencapsulation suspension biomimetic of milk structure for enhanced maternal and fetal absorptions of DHA to improve early brain development | |
US20050220857A1 (en) | Physiologically compatible, phospholipid-containing, stable and hard matrix | |
Cai et al. | Encapsulated microstructures of beneficial functional lipids and their applications in foods and biomedicines | |
KR20180128025A (ko) | 지용성 활성 성분을 포함하는 나노캡슐, 그 제조 방법 및 그 용도 | |
US10806742B2 (en) | Liquid phospholipid-containing compositions for the preparation of pharmaceuticals | |
CN113845677A (zh) | 一种乳液薄膜及其制备方法 | |
JP2007504197A (ja) | ホスファチジルセリン塩基の生理学的活性組成物 | |
JP2023518822A (ja) | pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法 | |
MX2011006978A (es) | Composiciones y aplicaciones de carotenoides de absorpcion y biodisponibilidad mejoradas. | |
CN1802102A (zh) | 用于预防和/或治疗脓毒症的肠内组合物 | |
JP4913340B2 (ja) | カプセル剤 | |
US20050232996A1 (en) | Matrix comprising a bioactive component containing phospholipid | |
CN106456783B (zh) | 含有欧米茄-3多不饱和脂肪酸和白藜芦醇的口服均相制剂 | |
JP2009079011A (ja) | ソフトカプセル充填用液状組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12780042 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26.02.2014) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12780042 Country of ref document: EP Kind code of ref document: A2 |